Shares of Endo International PLC (NASDAQ:ENDP) dropped 2.1% during trading on Thursday . The company traded as low as $21.53 and last traded at $21.63, with a volume of 6,063,861 shares. The stock had previously closed at $22.09.

ENDP has been the subject of a number of research analyst reports. JPMorgan Chase & Co. reissued an “overweight” rating and issued a $40.00 target price on shares of Endo International PLC in a report on Tuesday, July 26th. Goldman Sachs Group Inc. started coverage on Endo International PLC in a report on Monday, June 6th. They issued a “neutral” rating and a $20.00 price objective for the company. Stifel Nicolaus cut their price objective on Endo International PLC from $90.00 to $75.00 and set a “buy” rating for the company in a report on Friday, May 6th. Zacks Investment Research raised Endo International PLC from a “sell” rating to a “hold” rating in a report on Wednesday, July 20th. Finally, Morgan Stanley set a $15.00 price objective on Endo International PLC and gave the stock a “hold” rating in a report on Friday, August 5th. One research analyst has rated the stock with a sell rating, eleven have assigned a hold rating and eleven have assigned a buy rating to the company. The stock has a consensus rating of “Hold” and a consensus target price of $39.95.

The stock’s market cap is $4.68 billion. The company has a 50 day moving average price of $19.59 and a 200-day moving average price of $25.65.

Endo International PLC (NASDAQ:ENDP) last announced its quarterly earnings results on Monday, August 8th. The company reported $0.86 earnings per share for the quarter, topping the consensus estimate of $0.74 by $0.12. The company had revenue of $921 million for the quarter, compared to analyst estimates of $873.50 million. Endo International PLC’s revenue for the quarter was up 25.3% on a year-over-year basis. During the same period in the prior year, the business posted $1.08 earnings per share. Analysts anticipate that Endo International PLC will post $4.56 EPS for the current fiscal year.

An institutional investor recently raised its position in Endo International PLC stock. Ameriprise Financial Inc. increased its stake in Endo International PLC (NASDAQ:ENDP) by 350.9% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,458,860 shares of the company’s stock after buying an additional 1,913,553 shares during the period. Ameriprise Financial Inc. owned 1.09% of Endo International PLC worth $150,532,000 at the end of the most recent quarter.

Endo International PLC, formerly Endo Health Solutions Inc is a specialty healthcare solutions company focused on branded and generic pharmaceuticals, devices and services. The Company has a portfolio of branded pharmaceuticals that includes brands, such as Lidoderm, Opana ER, Voltaren Gel, Percocet, Frova, Supprelin LA, Vantas, Valstar and Fortesta Gel.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.